188 related articles for article (PubMed ID: 37552607)
1. Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies.
Restifo D; McDermott JR; Cvetkovic D; Dos Santos T; Ogier C; Surumbayeva A; Handorf EA; Schimke C; Ma C; Cai KQ; Olszanski AJ; Kathad U; Bhatia K; Sharma P; Kulkarni A; Astsaturov I
Mol Cancer Ther; 2023 Oct; 22(10):1182-1190. PubMed ID: 37552607
[TBL] [Abstract][Full Text] [Related]
2. LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency.
Kulkarni A; Zhou J; Biyani N; Kathad U; Banerjee PP; Srivastava S; Prucsi Z; Solarczyk K; Bhatia K; Ewesuedo RB; Sharma P
Cancer Res Commun; 2024 May; 4(5):1199-1210. PubMed ID: 38630886
[TBL] [Abstract][Full Text] [Related]
3. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
4. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
5. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
6. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
[TBL] [Abstract][Full Text] [Related]
7. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.
Lal S; Zarei M; Chand SN; Dylgjeri E; Mambelli-Lisboa NC; Pishvaian MJ; Yeo CJ; Winter JM; Brody JR
Sci Rep; 2016 Sep; 6():33323. PubMed ID: 27616351
[TBL] [Abstract][Full Text] [Related]
8. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
Shui L; Li X; Peng Y; Tian J; Li S; He D; Li A; Tian B; Li M; Gao H; An N; Yi C; Cao D
J Transl Med; 2021 Jul; 19(1):301. PubMed ID: 34247626
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing.
Jiang H; Huang F; Chen X; Zhang L; Shen M; Pan B; Wang B; Guo W
Mol Genet Genomic Med; 2023 Jul; 11(7):e2170. PubMed ID: 36978154
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
[TBL] [Abstract][Full Text] [Related]
11. The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.
Kulkarni A; McDermott JR; Kathad U; Modali R; Richard JP; Sharma P; Bhatia K
Oncotarget; 2021 Apr; 12(8):791-806. PubMed ID: 33889302
[TBL] [Abstract][Full Text] [Related]
12. DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives.
Stoof J; Harrold E; Mariottino S; Lowery MA; Walsh N
Front Cell Dev Biol; 2021; 9():749490. PubMed ID: 34712667
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma.
Lal B; Kulkarni A; McDermott J; Rais R; Alt J; Wu Y; Lopez-Bertoni H; Sall S; Kathad U; Zhou J; Slusher BS; Bhatia K; Laterra J
Clin Cancer Res; 2023 Oct; 29(20):4209-4218. PubMed ID: 37494541
[TBL] [Abstract][Full Text] [Related]
14. DNA damage response and repair in pancreatic cancer development and therapy.
Rahnamay Farnood P; Danesh Pazhooh R; Asemi Z; Yousefi B
DNA Repair (Amst); 2021 Jul; 103():103116. PubMed ID: 33882393
[TBL] [Abstract][Full Text] [Related]
15. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.
Armstrong SA; Schultz CW; Azimi-Sadjadi A; Brody JR; Pishvaian MJ
Mol Cancer Ther; 2019 Nov; 18(11):1899-1908. PubMed ID: 31676541
[TBL] [Abstract][Full Text] [Related]
16. LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.
Zhou J; Sturtevant D; Love C; Kulkarni A; Biyani N; Kathad U; Thacker E; Dave S; Bhatia K
Oncotarget; 2023 Jun; 14():597-611. PubMed ID: 37306526
[TBL] [Abstract][Full Text] [Related]
17. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer.
Dreyer SB; Upstill-Goddard R; Paulus-Hock V; Paris C; Lampraki EM; Dray E; Serrels B; Caligiuri G; Rebus S; Plenker D; Galluzzo Z; Brunton H; Cunningham R; Tesson M; Nourse C; Bailey UM; Jones M; Moran-Jones K; Wright DW; Duthie F; Oien K; Evers L; McKay CJ; McGregor GA; Gulati A; Brough R; Bajrami I; Pettitt S; Dziubinski ML; Candido J; Balkwill F; Barry ST; Grützmann R; Rahib L; ; ; Johns A; Pajic M; Froeling FEM; Beer P; Musgrove EA; Petersen GM; Ashworth A; Frame MC; Crawford HC; Simeone DM; Lord C; Mukhopadhyay D; Pilarsky C; Tuveson DA; Cooke SL; Jamieson NB; Morton JP; Sansom OJ; Bailey PJ; Biankin AV; Chang DK
Gastroenterology; 2021 Jan; 160(1):362-377.e13. PubMed ID: 33039466
[TBL] [Abstract][Full Text] [Related]
18. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
Colbert LE; Petrova AV; Fisher SB; Pantazides BG; Madden MZ; Hardy CW; Warren MD; Pan Y; Nagaraju GP; Liu EA; Saka B; Hall WA; Shelton JW; Gandhi K; Pauly R; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Curran WJ; Landry JC; Maithel SK; Yu DS
Cancer Res; 2014 May; 74(10):2677-87. PubMed ID: 24626090
[TBL] [Abstract][Full Text] [Related]
19. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
20. Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
Schmitt A; Feldmann G; Zander T; Reinhardt HC
Oncol Res Treat; 2018; 41(10):619-625. PubMed ID: 30286473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
